Keos Lumbar IBFD
Device Facts
| Record ID | K160631 |
|---|---|
| Device Name | Keos Lumbar IBFD |
| Applicant | Keos |
| Product Code | MAX · Orthopedic |
| Decision Date | Jul 15, 2016 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 888.3080 |
| Device Class | Class 2 |
| Attributes | Therapeutic |
Indications for Use
Keos Lumbar IBFD is indicated for spinal fusion procedure at one or two contiguous levels (L2-S1) in skeletally mature patients with degenerative disc disease (DDD). DDD is defined as discogenic pain with degeneration of the disc confirmed by patient history and radiographic studies. DDD may also have up to Grade 1 spondylolisthesis or retrolisthesis at the involved levels. These patients may have had a previous non-fusion spinal surgery at the involved spinal level(s). The Keos Lumbar IBFD is intended to be used with supplemental spinal fixation systems that have been cleared for lumbosacral spine (i.e., posterior pedicle screws and rod systems, anterior plate systems, and anterior screw and rod systems). The device(s) is intended to be used with autogenous bone graft. Patients should have at least six (6) months of non-operative treatment prior to treatment with an intervertebral cage. The Keos Lumbar IBFD can be used in one of two methods: Transforaminal Lumbar Interbody Fusion (TLIF) Used as a TLIF, a single device is implanted in the appropriate location (L2-S1) to provide support for a transforaminal approached surgery. Posterior Lumbar Interbody Fusion (PLIF) Used as a PLIF, two devices are implanted in the appropriate locations (L2-S1) to provided support to the spine for a posterior surgery.
Device Story
Intervertebral body fusion device (IBFD) designed to maintain disc space distraction; used in conjunction with supplemental spinal fixation (e.g., pedicle screws, plates, rods) and autogenous bone graft. Device consists of PEEK cages with hollow centers for graft material; superior/inferior ridges grip endplates to prevent expulsion; includes embedded tantalum x-ray markers. Implanted via TLIF (single device) or PLIF (two devices) approach in L2-S1 region. Used by surgeons in clinical/OR settings. Provides structural support to spine during fusion process; benefits patients by facilitating stabilization in degenerative disc disease cases.
Clinical Evidence
No clinical tests were performed. Evidence is based on bench testing, including static and dynamic compression (ASTM F2077), compression shear (ASTM F2077), subsidence (ASTM F2267), and static expulsion testing.
Technological Characteristics
Materials: PEEK-OPTIMA and PEEK-OPTIMA LT120HA (ASTM F2026); tantalum markers (ASTM F560). Form factor: Cages of various fixed heights/shapes. Sterilization: Non-sterile, autoclaveable (SAL 10^-6 per ISO 17665).
Indications for Use
Indicated for spinal fusion at one or two contiguous levels (L2-S1) in skeletally mature patients with degenerative disc disease (DDD), including those with up to Grade 1 spondylolisthesis or retrolisthesis. Patients may have had prior non-fusion surgery at the involved level. Requires at least 6 months of prior non-operative treatment.
Regulatory Classification
Identification
An intervertebral body fusion device is an implanted single or multiple component spinal device made from a variety of materials, including titanium and polymers. The device is inserted into the intervertebral body space of the cervical or lumbosacral spine, and is intended for intervertebral body fusion.
Special Controls
*Classification.* (1) Class II (special controls) for intervertebral body fusion devices that contain bone grafting material. The special control is the FDA guidance document entitled “Class II Special Controls Guidance Document: Intervertebral Body Fusion Device.” See § 888.1(e) for the availability of this guidance document.(2) Class III (premarket approval) for intervertebral body fusion devices that include any therapeutic biologic (e.g., bone morphogenic protein). Intervertebral body fusion devices that contain any therapeutic biologic require premarket approval. (c) *Date premarket approval application (PMA) or notice of product development protocol (PDP) is required.* Devices described in paragraph (b)(2) of this section shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.